NO20080371L - Fremgangsmate for a forutsi responsen overfor en behandling - Google Patents

Fremgangsmate for a forutsi responsen overfor en behandling

Info

Publication number
NO20080371L
NO20080371L NO20080371A NO20080371A NO20080371L NO 20080371 L NO20080371 L NO 20080371L NO 20080371 A NO20080371 A NO 20080371A NO 20080371 A NO20080371 A NO 20080371A NO 20080371 L NO20080371 L NO 20080371L
Authority
NO
Norway
Prior art keywords
marker gene
response
growth factor
treatment
patient
Prior art date
Application number
NO20080371A
Other languages
English (en)
Norwegian (no)
Inventor
Joachim Moecks
Andreas Strauss
Gerhard Zugmaier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080371(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20080371L publication Critical patent/NO20080371L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
NO20080371A 2005-08-12 2008-01-21 Fremgangsmate for a forutsi responsen overfor en behandling NO20080371L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12
PCT/EP2006/004950 WO2007019899A2 (en) 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor

Publications (1)

Publication Number Publication Date
NO20080371L true NO20080371L (no) 2008-05-09

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080371A NO20080371L (no) 2005-08-12 2008-01-21 Fremgangsmate for a forutsi responsen overfor en behandling

Country Status (32)

Country Link
US (2) US7700299B2 (hr)
EP (2) EP1915460B1 (hr)
JP (1) JP2009504142A (hr)
KR (2) KR20080034922A (hr)
CN (2) CN101705287A (hr)
AR (1) AR057323A1 (hr)
AT (2) ATE539171T1 (hr)
AU (2) AU2006281746B2 (hr)
BR (1) BRPI0615001A2 (hr)
CA (1) CA2616913A1 (hr)
CL (1) CL2010000720A1 (hr)
CR (1) CR9686A (hr)
CY (1) CY1111612T1 (hr)
DE (1) DE602006019265D1 (hr)
DK (1) DK1915460T3 (hr)
EC (1) ECSP088171A (hr)
ES (1) ES2356066T3 (hr)
HR (1) HRP20110171T1 (hr)
IL (1) IL188923A0 (hr)
MA (1) MA31549B1 (hr)
MX (1) MX2008001926A (hr)
NO (1) NO20080371L (hr)
NZ (1) NZ565270A (hr)
PL (1) PL1915460T3 (hr)
PT (1) PT1915460E (hr)
RS (1) RS51859B (hr)
RU (2) RU2408735C2 (hr)
SI (1) SI1915460T1 (hr)
TW (1) TW200741010A (hr)
UA (1) UA93989C2 (hr)
WO (1) WO2007019899A2 (hr)
ZA (1) ZA201102688B (hr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PL217410B1 (pl) 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20150043558A (ko) 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
SI1850874T1 (sl) * 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP1917528B1 (en) * 2005-08-24 2011-08-17 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
AU2008223069B2 (en) * 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
AU2008341050B2 (en) * 2007-12-26 2013-10-24 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0906049A8 (pt) 2008-03-14 2018-06-26 Genentech Inc método para determinar se um câncer em um paciente é resistente ao tratamento com um agente antimitótico, método para tratar um paciente com câncer que é resistente ao agente antimitótico e método de tratamento
DK2288727T3 (da) * 2008-05-14 2013-10-21 Genomic Health Inc Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP5858984B2 (ja) * 2010-04-18 2016-02-10 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ＥｒｂＢ／ＥｒｂＢリガンドに関連する疾患を治療するための分子及びその分子を使用する方法
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
ES2834986T3 (es) * 2011-01-07 2021-06-21 Anji Pharma Us Llc Terapias basadas en ligandos de receptores quimiosensoriales
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
SG10201606756PA (en) 2011-10-14 2016-10-28 Genentech Inc Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
CN105121471A (zh) 2013-04-16 2015-12-02 豪夫迈·罗氏有限公司 帕妥珠单抗变体及其评估
US20160175401A1 (en) * 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
EP2876442A1 (en) 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
WO2017014810A1 (en) * 2015-07-17 2017-01-26 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
JP2019532999A (ja) 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳がんの治療
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
AU2018210312B2 (en) 2017-01-17 2020-03-19 F. Hoffmann-La Roche Ag Subcutaneous HER2 antibody formulations
EP3589661B1 (en) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
US20210189398A1 (en) 2018-05-25 2021-06-24 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
WO2024036234A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
EP1106183A3 (en) 1996-10-18 2001-09-12 Genentech, Inc. Antibodies to erbB2 and their therapeutic uses
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DE10084743T1 (de) 1999-06-25 2002-08-14 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern
EP2241636A1 (en) 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2490758C (en) * 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
DE03808454T1 (de) * 2002-12-11 2006-01-26 Ventana Medical Systems, Inc., Tucson Verfahren zur voraussage der auswirkung der her2-gezielten therapie
AU2004211955B2 (en) 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
CA2521082A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
EP1682675A2 (en) 2003-10-28 2006-07-26 Bayer HealthCare AG Methods and compositions for the response prediction of malignant neoplasia to treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor

Also Published As

Publication number Publication date
PL1915460T3 (pl) 2011-05-31
US7700299B2 (en) 2010-04-20
RU2408735C2 (ru) 2011-01-10
ATE539171T1 (de) 2012-01-15
US20070037228A1 (en) 2007-02-15
HRP20110171T1 (hr) 2011-04-30
ATE493514T1 (de) 2011-01-15
JP2009504142A (ja) 2009-02-05
TW200741010A (en) 2007-11-01
EP2196547B1 (en) 2011-12-28
EP1915460B1 (en) 2010-12-29
PT1915460E (pt) 2011-03-17
AU2006281746A1 (en) 2007-02-22
EP2196547A1 (en) 2010-06-16
MX2008001926A (es) 2008-03-24
CY1111612T1 (el) 2015-10-07
DK1915460T3 (da) 2011-01-31
UA93989C2 (ru) 2011-03-25
CN101405405A (zh) 2009-04-08
AU2006281746B2 (en) 2011-06-23
ES2356066T3 (es) 2011-04-04
CN101705287A (zh) 2010-05-12
CL2010000720A1 (es) 2010-12-03
WO2007019899A2 (en) 2007-02-22
CA2616913A1 (en) 2007-02-22
EP1915460A2 (en) 2008-04-30
ZA201102688B (en) 2012-01-25
WO2007019899A3 (en) 2007-04-05
KR20080034922A (ko) 2008-04-22
RU2008108907A (ru) 2009-09-20
NZ565270A (en) 2011-05-27
IL188923A0 (en) 2008-08-07
ECSP088171A (es) 2008-03-26
RU2010115252A (ru) 2011-10-27
US20100112603A1 (en) 2010-05-06
DE602006019265D1 (de) 2011-02-10
BRPI0615001A2 (pt) 2011-04-26
MA31549B1 (fr) 2010-08-02
AR057323A1 (es) 2007-11-28
WO2007019899A8 (en) 2010-08-05
RS51859B (en) 2012-02-29
KR20110074921A (ko) 2011-07-04
SI1915460T1 (sl) 2011-04-29
AU2011202339A1 (en) 2011-06-09
CR9686A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20080371L (no) Fremgangsmate for a forutsi responsen overfor en behandling
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
EA201170933A1 (ru) Анализ нуклеиновых кислот, полученных из единичных клеток
EP2021534A4 (en) ESTIMATE AND REDUCE THE RISK OF GRAFT VERSUS HOST REACTION
ATE543463T1 (de) Prothese und einsetzsystem
SE0301951D0 (sv) New method
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
NZ587750A (en) Molecular diagnosis and classification of malignant melanoma
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE510029T1 (de) Verfahren zur analyse von nukleinsäuren
WO2005069187A3 (en) Methods and system for the identification and characterization of peptides and their functional relationships by use of measures of correlation
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2009132928A3 (en) Molecular markers for cancer prognosis
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
ATE456797T1 (de) Verwendung von nogo-c bei der beurteilung von herzversagen
GB0617116D0 (en) Method of diagnosis
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
GB0617117D0 (en) Method of diagnosis
WO2007127002A3 (en) Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application